GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Total Current Liabilities

Mapi - Pharma (Mapi - Pharma) Total Current Liabilities : $2.21 Mil (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Mapi - Pharma's total current liabilities for the quarter that ended in Jun. 2015 was $2.21

Mapi - Pharma Total Current Liabilities Historical Data

The historical data trend for Mapi - Pharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Total Current Liabilities Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Total Current Liabilities
4.72 5.71 4.26

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Total Current Liabilities 4.72 5.71 - 4.26 2.21

Mapi - Pharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Mapi - Pharma's Total Current Liabilities for the fiscal year that ended in Dec. 2014 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.494+0
+Other Current Liabilities+Current Deferred Liabilities
=3.769+0
=4.26

Mapi - Pharma's Total Current Liabilities for the quarter that ended in Jun. 2015 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.214+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Mapi - Pharma Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Total Current Liabilities
Comparable Companies
NUVPF ADMD RSPI YBAO ULUR NRXCF ACUR LBLTF PUFXF BKIT RLMD IGC MYOS CBICF SBFM PVCT AQSZF PTLF AOLS APRI
Traded in Other Exchanges
N/A
Address
Website
http://www.mapi-pharma.com
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Headlines